Marie-Laure Yaspo heads an independent research group at the Max Planck Institute for Molecular Genetics in Berlin. She is also one of the founders and Chief Scientific Officer of Alacris Theranostics, a Berlin based company founded in 2008. Alacris Theranostics works towards developing novel approaches in precision medicine with long-standing expertise in interdisciplinary approaches, combining sequencing technologies, large-scale operations, advanced computing, high dimensional data analytics and bioinformatics systems.
The Yaspo research group focuses on cancer genomics and system biology of cancer, with a translational perspective in personalized medicine. Based on NGS technologies, our interests are centered on dissecting molecular landscapes of tumors for identifying pathway components and biomarkers associated with malignancy,, and on exploring gene regulation
networks operating in specific cancer entities. Ong ing cooperative projects address various aspects of cancer genomics in metastatic melanoma, early-onset prostate cancer, medulloblastoma, pediatric leukemia, and colorectal cancer. We have developed powerful integrative NGS analysis pipelines exploiting simultaneously genome and transcriptome information.
In particular we promote the use of RNAseq in tumor profiling, detecting the consequences of somatic events at the gene expression levels, such as gene fusions, alternatively spliced isoforms, long non-coding RNAs, and epigenetic dysregulations. Beyond primary tumor chracterisation, we are interested in identifying the nature of the stromal niche and immune infiltrates
in various tumors, and in evaluating to which extend patient-derived model systems cell or xenografts, used in drug sensitivity assays, recapitulate the features of their donors.
Besides, we are developing NGS-based methods allowing a deep characterisation of human immune cell repertoires and therefore the immune status in health and disease.